MapLight Therapeutics/$MPLT
1D1W1MYTD1Y5YMAX
Capital at risk
About MapLight Therapeutics
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
- Ticker
- $MPLT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 133
- Headquarters
- Redwood City, United States
- Website
- www.maplightrx.com
MPLT Metrics
BasicAdvanced
$731M
-
-$7.42
-
-
Price and volume
Market cap
$731M
52-week high
$40.43
52-week low
$9.10
Average daily volume
596K
Financial strength
Current ratio
16.523
Quick ratio
15.794
Long term debt to equity
0.002
Total debt to equity
0.006
Profitability
EBITDA (TTM)
-242.343
Management effectiveness
Return on assets (TTM)
-67.11%
Return on equity (TTM)
-111.55%
Valuation
Price to book
1.72
Price to tangible book (TTM)
1.72
Price to free cash flow (TTM)
-2.326
Free cash flow yield (TTM)
-42.99%
Free cash flow per share (TTM)
-5.653
Growth
Earnings per share change (TTM)
-93.89%
What the Analysts think about MPLT
Analyst ratings (Buy, Hold, Sell) for MapLight Therapeutics stock.
Analyst projections of the future price of MapLight Therapeutics stock.
Bulls say / Bears say
The twice-daily 210/3 mg dose of ML-007C-MA met the Phase 2 ZEPHYR trial’s primary endpoint and achieved key secondary measures (effect size 0.37 vs placebo, p = 0.015; CGI-S p = 0.002; PANSS Positive Marder p = 0.012), with favourable tolerability and no serious adverse events, supporting a registrational Phase 3 ZEPHYR-2 trial (finance.yahoo.com) (Reuters)
BUZZ-Needham initiated coverage with a Buy rating and $37 price target, highlighting ML-007C-MA’s differentiated tolerability and convenience versus Bristol Myers’ Cobenfy and forecasting peak sales of $1.5 billion for schizophrenia and $2.4 billion for Alzheimer’s disease psychosis by 2035 (sahmcapital.com) (Reuters)
On August 13, 2026, MapLight raised $150 million in a private placement financing, bolstering its cash position to $351.3 million and extending runway through 2028 to fully fund ML-007C-MA’s planned Phase 3 ZEPHYR-2 and Phase 2 VISTA trials (investing.com) (Reuters)
The once-daily 330/6 mg arm of ML-007C-MA failed to meet ZEPHYR’s primary endpoint of symptom improvement, triggering a 55% premarket share plunge and raising concerns over optimal dosing and commercial viability (finance.yahoo.com) (Reuters)
MapLight’s ML-004 failed to achieve its primary social communication endpoint in the Phase 2 IRIS trial for autism spectrum disorder, representing a significant pipeline setback and potential resource reallocation (investing.com) (Reuters)
Morgan Stanley downgraded MapLight to Equalweight from Overweight and cut its price target to $21 (from $34), citing mixed ZEPHYR results, underscoring the stock’s vulnerability to clinical readouts (investing.com) (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
MPLT Financial Performance
Revenues and expenses
MPLT Earnings Performance
Company profitability
Upcoming events
No upcoming events
MPLT News
AllArticlesVideos
Funds containing MPLT
Fund name | Fund size | $MPLT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.